Cargando…
Refinement of diagnosis and supporting evidence for the use of immunotherapy through sequential biopsies in a case of EML4-ALK positive lung cancer
In this case report, we describe a tortuous, yet rare, treatment process of the patient. The first biopsy of the patient suggested inflammatory myofibroblastic tumor, ALK (D5F3) positive. Considering the benign progression of the disease, and no indication for surgical resection, oral prednisone was...
Autores principales: | Song, Peng, Zhang, Jingcheng, Zhang, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489643/ https://www.ncbi.nlm.nih.gov/pubmed/31114237 http://dx.doi.org/10.2147/OTT.S203192 |
Ejemplares similares
-
Alectinib treatment response in lung adenocarcinoma patient with novel EML4‐ALK variant
por: Song, Peng, et al.
Publicado: (2018) -
Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020) -
Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
por: Tanizaki, J, et al.
Publicado: (2012) -
Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022) -
Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
por: Papageorgiou, Savvas, et al.
Publicado: (2022)